Triapine
Trials 34
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 37 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Triapine\^ | “I. Determine the 3- and 6-month survival rate of patients with locally advanced or metastatic adenocarcinoma of the pancreas treated with 3-AP (Triapine\^®) as first- or...” NCT00085371 ↗ |
| Known as | 3-aminopyridine-2-carboxaldehyde thiosemicarbazone | “A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer” NCT00016874 ↗4“A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion” NCT00006218 ↗ “A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin” NCT00024323 ↗ “A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer” NCT00054015 ↗ “3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine” PMID 17640728 ↗ Jul 2007 |
| Known as | 3-AP | “I. Determine the 3- and 6-month survival rate of patients with locally advanced or metastatic adenocarcinoma of the pancreas treated with 3-AP (Triapine\^®) as first- or...” NCT00085371 ↗11“3-AP may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth and may help cytarabine kill more cancer cells by making them more sensitive...” NCT00064090 ↗ “A Phase I Study Of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) In Combination With Cisplatin And Paclitaxel In Patients With Advanced And Metastatic Cancer” NCT00016874 ↗ “A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Cancer Patients Using a 96-Hour Intravenous Continuous Infusion” NCT00006218 ↗ “A Phase I Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) Administered Daily x 5 in Combination With Cisplatin” NCT00024323 ↗ “A Phase II Study of 3-Aminopyridine-2-Carboxaldehyde Thiosemicarbazone (3-AP, Triapine) in Patients With Advanced Prostate Cancer” NCT00054015 ↗ “3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine) in combination with the nucleoside analog fludarabine” PMID 17640728 ↗ Jul 2007 “Patients receive 3-AP (Triapine®) IV over 2 hours on days 1-4 and 15-18.” NCT00075660 ↗ “Patients receive 3-AP (Triapine) IV over 2 hours on days 1-4.” NCT00077545 ↗ “Patients receive 3-AP (Triapine®) IV over 2 hours” NCT00078975 ↗ “3-AP (Triapine®)” NCT00077415 ↗ |
| Known as | NSC# 663249 | “A Phase 0 Window-of-Opportunity Pharmacodynamic Trial of Triapine (NSC# 663249) in Uterine Corpus Serous Adenocarcinoma” NCT04494113 ↗1“A Phase II Study of Triapine (NSC 663249) in Previously Untreated Patients With Recurrent Renal Cell Carcinoma” NCT00075660 ↗ |
| Known as | OCX-0191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL231616 ↗ |
| Known as | OCX-191 | ChEMBL registry synonym — accepted as the source's own label CHEMBL231616 ↗ |
| Known as | PAN-811 | ChEMBL registry synonym — accepted as the source's own label CHEMBL231616 ↗ |
| Action | Inhibit | “intravenous (i.v.) triapine, a small-molecule RNR inhibitor” PMID 27878356 ↗ Nov 2016 |
| Modality | Small molecule | “intravenous (i.v.) triapine, a small-molecule RNR inhibitor” PMID 27878356 ↗ Nov 2016 |
| Route | Intravenous | “Patients receive 3-AP IV continuously over 96 hours.” NCT00006218 ↗ |